[Federal Register Volume 70, Number 72 (Friday, April 15, 2005)]
[Notices]
[Page 19964]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-7542]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive License: Therapeutics for the 
Treatment of Retinopathy

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 
Part 404.7(a)(1)(i), announces that the National Institutes of Health, 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license to practice the inventions embodied in 1. E-223-
1992/0-US-01, ``SIGNAL TRANSDUCTION INHIBITOR COMPOUNDS'', by Elise 
Kohn, Lance Liotta, Christian Felder, issued Pat No. 5,359,078 (issue 
date October 25, 1994); 2. E-223-1992/0-US-02, ``SIGNAL TRANSDUCTION 
INHIBITOR TRIAZOLE AND DIAZOLE COMPOUNDS'' by Elise Kohn, Lance Liotta, 
Christian Felder, issued Pat No. 5,482,954 (issue date January 9, 
1996); 3. E-223-1992/0-US-03, ``SIGNAL TRANSDUCTION INHIBITOR 1,2,3,-
TRIAZOLO COMPOUNDS'' by Elise Kohn, Lance Liotta, Christian Felder, 
issued Pat No. 5,498,620, (issued date March 12, 1996); 4. E-223-1992/
0-US-04, ``SIGNAL TRANSDUCTION INHIBITOR COMPOUNDS'' by Elise Kohn, 
Lance Liotta, Christian Felder, issued Pat No 5,705,514 (issued date 
January 6, 1998); 5. E-223-1992/0-US-05, ``SIGNAL TRANSDUCTION 
INHIBITOR COMPOUNDS'' by Elise Kohn, Lance Liotta, Christian Felder, 
issued Pat No 5,880,129 (issued date March 9, 1999); 6. E-068-1991/1-
US-01, ``METHOD FOR INHIBITING METALLOPROTEINASE EXPRESSION'' by Elise 
Kohn, Lance Liotta, issued Pat No. Pat No. 5,602,156 (issued date 
February 11, 1997); 7. E-220-1993/1-US-01 ``METHOD FOR INHIBITING 
ANGIOGENESIS'' by Elise Kohn, Lance Liotta and Riccardo Alessandro 
issued patent No 5,744,492 (issue date April 28,1998), to RFE Pharma, 
having a place of business in Framingham, MA. The patent rights in 
these inventions have been assigned to the United States of America.
    The prospective exclusive license territory may be worldwide, and 
the field of use may be limited to therapeutics for the treatment of 
retinopathy.

DATES: Only written comments and/or license applications which are 
received by the National Institutes of Health on or before June 14, 
2005, will be considered.

ADDRESSES: Requests for copies of the patent and/or patent 
applications, inquiries, comments and other materials relating to the 
contemplated exclusive license should be directed to: John Stansberrry, 
Ph.D., Technology Licensing Specialist, Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, MD 20852-3804; telephone: (301) 435-5236; Facsimile: (301) 
402-0220; e-mail: [email protected].

SUPPLEMENTARY INFORMATION: The present invention provides composition 
of matter claims and methods for inhibiting angiogenesis in a host 
using carboxyamido-triazole (CAI) and related analogs. The calcium 
influx inhibitor and matrix metalloproteinase expression inhibitor, 
CAI, has shown anti-cancer activity due to its ability to influence 
signal transduction pathways. CAI and CAI analogues inhibit endothelial 
cell adhesion and migration in response to basement membrane components 
and thus block new vessel formation. Pharmaceutical applications 
directed to inhibiting angiogenesis offer novel approaches to the 
treatment of cancer, diabetic retinopathy, hemangiomata, vasculidities 
and other diseases associated with angiogenesis.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless within sixty 
(60) days from the date of this published notice, the NIH receives 
written evidence and argument that establish that the grant of the 
license would not be consistent with the requirements of 35 U.S.C. 209 
and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: April 6, 2005.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 05-7542 Filed 4-14-05; 8:45 am]
BILLING CODE 4140-01-P